<DOC>
	<DOC>NCT02813252</DOC>
	<brief_summary>This study will provide long-term follow-up for patients who have received treatment with JCAR015 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of JCAR015 for evaluation of delayed adverse events, presence of persisting JCAR015 vector sequences, and survival.</brief_summary>
	<brief_title>Long-Term Follow-up Study for Patients Previously Treated With JCAR015</brief_title>
	<detailed_description />
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<criteria>Inclusion criteria: Patients who have received at least one dose of JCAR015 in a previous treatment protocol. Patients who have provided informed consent for the longterm followup study prior to study participation. Exclusion criteria: None. All patients who have previously received JCAR015 treatment are eligible for this longterm followup study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>long-term follow-up</keyword>
	<keyword>chimeric antigen receptor (CAR) T cells</keyword>
	<keyword>JCAR015</keyword>
</DOC>